Previous 10 | Next 10 |
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara ...
Alto Ingredients (ALTO) -16% on Q4 earnings releaseMediciNova (MNOV) -16%.Savara (SVRA) -13% on proposed public offering of stockJust Energy Group (JE) -13% after announces Toronto Stock Exchange and New York Stock Exchange have commenced delisting proceedings.Enveric...
Savara (SVRA) intends to offer and sell, common shares in a public offering.In addition, Savara is offering the right to purchase pre-funded warrants in lieu of common stock.Underwriters' over-allotment is an additional 15% of shares.Actual size, price and terms are not yet determined.Net pro...
The microcap company focused on orphan lung disease Savara (SVRA) has disclosed additional information regarding its IMPALA 2 clinical trial.The Phase 3 trial is designed to compare the safety and efficacy of once-daily inhalational administration of molgramostim 300 µg against...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain investors the right to purchase pre-...
Penny Stocks Are Trading Higher After Market-Wide Dip We talk about the relation of penny stocks to broader markets. In general, even when there’s a large sell-off in blue-chips, cheaper stocks tend to move on their own accord. While this may be true 99% of the time, there ar...
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...
Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax L...
Savara (SVRA) plummets 26% in premarket in reaction to topline data from Phase 3 AVAIL study evaluating AeroVanc (vancomycin hydrochloride inhalation powder) in cystic fibrosis patients with methicillin-resistant Staphylococcus aureus ((MRSA)) lung infection. The study missed the primary...
Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...